ZNAK SAGITE — više od fantastike — edicija, časopis, knjižara...

priznajem da su mi tvoji "science" postovi bili u glavi kad se pričalo kako se nauka prezentuje na TV-u. oprostićeš mi što sam zlica, znam!

Pa, ja radim sa onim što (donekle) razumem, a pošto sam neobrazovan toga nema mnogo    Pa je gomila toga što kačim zaista vrlo sumnjivog epistemološkog statusa, ali računam da ljudi shvataju da je u pitanju tek po koji kurio, nikako ne neka mudrost koja je nedovodljiva u pitanje i na kojoj treba da zasnuju ostatke svojih života.

ajde mehane, znam te (još dok gojazan nisi bio!)

U.S. sees first case of bacteria resistant to last-resort antibiotic 

QuoteU.S. health officials on Thursday reported the first case in the country of a patient with an infection resistant to a last-resort antibiotic, and expressed grave concern that the superbug could pose serious danger for routine infections if it spreads. "We risk being in a post-antibiotic world," said Thomas Frieden, director of the U.S. Centers for Disease Control and Prevention, referring to the urinary tract infection of a 49-year-old Pennsylvania woman who had not traveled within the prior five months. Frieden, speaking at a National Press Club luncheon in Washington, D.C., said the bacteria was resistant to colistin, an antibiotic that is reserved for use against "nightmare bacteria." The infection was reported Thursday in a study appearing in Antimicrobial Agents and Chemotherapy, a publication of the American Society for Microbiology. It said the superbug itself had first been infected with a tiny piece of DNA called a plasmid, which passed along a gene called mcr-1 that confers resistance to colistin. "(This) heralds the emergence of truly pan-drug resistant bacteria," said the study, which was conducted by the Walter Reed National Military Medical Center. "To the best of our knowledge, this is the first report of mcr-1 in the USA." The patient visited a clinic on April 26 with symptoms of a urinary tract infection, according to the study, which did not describe her current condition. Authors of the study could not immediately be reached for comment. The study said continued surveillance to determine the true frequency of the gene in the United States is critical.  "It is dangerous and we would assume it can be spread quickly, even in a hospital environment if it is not well contained," said Dr. Gail Cassell, a microbiologist and senior lecturer at Harvard Medical School. But she said the potential speed of its spread will not be known until more is learned about how the Pennsylvania patient was infected, and how present the colistin-resistant superbug is in the United States and globally. "MEDICINE CABINET IS EMPTY FOR SOME" In the United States, antibiotic resistance has been blamed for at least 2 million illnesses and 23,000 deaths annually. The mcr-1 gene was found last year in people and pigs in China, raising alarm. The potential for the superbug to spread from animals to people is a major concern, Cassell said. For now, Cassell said people can best protect themselves from it and from other bacteria resistant to antibiotics by thoroughly washing their hands, washing fruits and vegetables thoroughly and preparing foods appropriately. Experts have warned since the 1990s that especially bad superbugs could be on the horizon, but few drugmakers have attempted to develop drugs against them.  Frieden said the need for new antibiotics is one of the more urgent health problems, as bugs become more and more resistant to current treatments. "The more we look at drug resistance, the more concerned we are," Frieden added. "The medicine cabinet is empty for some patients. It is the end of the road for antibiotics unless we act urgently."  Overprescribing of antibiotics by physicians and in hospitals and their extensive use in food livestock have contributed to the crisis. More than half of all hospitalized patients will get an antibiotic at some point during their stay. But studies have shown that 30 percent to 50 percent of antibiotics prescribed in hospitals are unnecessary or incorrect, contributing to antibiotic resistance.  Many drugmakers have been reluctant to spend the money needed to develop new antibiotics, preferring to use their resources on medicines for cancer and rare diseases that command very high prices and lead to much larger profits.  In January, dozens of drugmakers and diagnostic companies, including Pfizer (PFE.N), Merck & Co (MRK.N), Johnson & Johnson (JNJ.N) and GlaxoSmithKline (GSK.L), signed a declaration calling for new incentives from governments to support investment in development of medicines to fight drug-resistant superbugs. (This story corrects headline, first and third paragraphs to show bacteria is resistant to last-resort antibiotic colistin, not all antibiotics) (Reporting by Ransdell Pierson; Additional reporting by Bill Berkrot; Editing by Bernard Orr)

koliko vidim, našli su da je bakterija rezistentna na colistin (ima mrc-1 gen plus je taj gen u plazmidu što joj omogućava brz horizontalni prelaz sa bakterije na bakteriju) al kad su je testirali na ukupno 20 antibiotika, 6 je odradilo posao.
biće da ipak imamo još malo vremena da pronađemo nove antibiotike ili da se malo bolje pozabavimo kako da upotrebimo bakteriofage (viruse koji napadaju bakterije) u ovu svrhu.

 Stanford researchers 'stunned' by stem cell experiment that helped stroke patient walk 

Quote

Stanford researchers studying the effect of stem cells injected directly into the brains of stroke patients said Thursday that they were "stunned" by the extent to which the experimental treatment restored motor function in some of the patients. While the research involved only 18 patients and was designed primarily to look at the safety of such a procedure and not its effectiveness, it is creating significant buzz in the neuroscience community because the results appear to contradict a core belief about brain damage — that it is permanent and irreversible.
The results, published in the journal Stroke, could have implications for our understanding of an array of disorders including traumatic brain injury, spinal cord injury and Alzheimer's if confirmed in larger-scale testing.
The work involved patients who had passed the critical six-month mark when recoveries generally plateau and there are rarely further improvements. This is the point at which therapies are typically stopped as brain circuits are thought to be dead and unable to be repaired. Each participant in the study had suffered a stroke beneath the brain's outermost layer and had significant impairments in moving their arms and-or legs. Some participants in the study had had a stroke as long as three to five years before the experimental treatment.
[Stem cell study: Up to 90 percent of cancers not 'bad luck,' but due to lifestyle choices, environment]
The one-time therapy involved surgeons drilling a hole into the study participants' skulls and injecting stem cells in several locations around the area damaged by the stroke. These stem cells were harvested from the bone marrow of adult donors. While the procedure sounds dramatic, it is considered relatively simple as far as brain surgery goes. The patients were conscious the whole time and went home the same day.
They suffered minimal adverse effects such as temporary headaches, nausea and vomiting. One patient experienced some fluid buildup from the procedure that had to be drained but recovered fully from the issue. The volunteers were then tested at one month, six and 12 months after surgery using brain imaging and several standard scales that look at speech, vision, motor ability and other aspects of daily functioning.
Gary Steinberg, the study's lead author and chair of neurosurgery at Stanford, said in an interview that while he is cautious about "overselling" the results of such a small study, his team has been "stunned" that seven of the 18 patients experienced significant improvement in their abilities following treatment.
[Scientists create a new type of stem cell with only half a human's usual 46 chromosomes]
"Their recovery was not just a minimal recovery like someone who couldn't move a thumb now being able to wiggle it. It was much more meaningful. One 71-year-old wheelchair-bound patient was walking again," said Steinberg, who personally performed most of the surgeries.
He also recounted the progress of a much younger patient, age 39, who was two years post-stroke and had had such problems walking and speaking that she "did not want to get married to her boyfriend." "She was embarrassed about walking down the aisle," he explained. But after treatment, Steinberg said, "She's now walking much better and talking much better and she's married and pregnant."
Steinberg said that the study does not support the idea that the injected stem cells become neurons, as has been previously thought. Instead, it suggests that they seem to trigger some kind of biochemical process that enhances the brain's ability to repair itself.
"A theory is that they turn the adult brain into the neonatal brain that recovers well," he explained.
[Frightening images show the insidious way Zika appears to attack babies' brains]
Sean Savitz, a professor of neurosurgery at the University of Texas, said he was encouraged by the study but said there is a lot more work to be done to try to confirm the results and figure out the mechanism for the reaction. One major question, he said, is whether there is something about the stem cells that is stimulating the changes or whether it is simply the procedure itself inducing some other sort of biological reaction or a placebo effect.
Nicholas Boulis, a neurosurgeon and researcher at Emory University, said the study appears to support the idea that there may be latent pathways in the brain that can be reactivated — a theory that has been "working its way to the surface" over the past few years.
"There is certainly reason to be enthusiastic based on the magnitude of responses from these patients," he said.

There are close to 7 million so-called chronic stroke patients in the United States who are living with the aftermath of the damage to their brains and bodies from stroke. While there are several treatments that can be administered within hours or days of an incident in order to improve a patient's outcome, and physical therapy that can take place for a few months after that, there is very little doctors can do after that time.
Stem cells have been among the most promising new avenues of research. Huge improvements have been shown in animal models but results of the first human tests are just starting to come in. Earlier this month researchers at the University of Miami Miller School of Medicine reported that a year-long study of 48 patients found that infusing patients with stroke with stem cells through their carotid artery appeared to be safe.
The Stanford researchers have launched a larger randomized, double-blinded multicenter trial using the same procedure and have already begun to enroll patients. They are aiming for 156 total and say they hope to have results in as soon as two years.

moram malo da pofalim firmu

https://www.sciencedaily.com/releases/2016/06/160611125403.htm

QuoteWorld's first vaccine developed against Toxic Shock Syndrome

(Vienna, 11-06-2016) Toxic Shock Syndrome (TSS) is a severe circulatory and organ failure caused by bacterial toxins, usually triggered by bacteria from the Staphylococcus group. Researchers from MedUni Vienna's Department of Clinical Pharmacology, in collaboration with the company Biomedizinische Forschungsgesellschaft mbH in Vienna, have now developed the world's first safe and effective vaccine against this disease and successfully tested it in a Phase I trial. The promising results were recently published in the leading journal "The Lancet Infectious Diseases".

This syndrome was first described in the 1980s. General symptoms of sepsis or blood poisoning occurred in young women who had used so-called "super tampons" during their periods. This is why the syndrome was also known as "tampon disease". This subsequently led to the absorption capacity of tampons being regulated.

Staphylococci colonize nearly all of us, especially on our skin and mucous membranes. They are totally harmless to most people. "However, for people with weakened immune systems, they can cause serious diseases such as Toxic Shocks Syndrome," explains Martha Eibl, director of Biomedizinische Forschungsgesellscaft mbH and former university professor at the Institute for Immunology of the medical faculty of the University of Vienna. This affects dialysis patients, the chronically sick, people with liver diseases and people recovering after heart operations. "Nevertheless, in 50% of cases the disease is associated with menstruation in young women," says Bernd Jilma from MedUni Vienna's Department of Clinical Pharmacology.

The vaccine, which has now been found to be safe and effective – and to have practically no side effects – in a clinical Phase I trial, and has been tested on 46 young men and women, was developed from a detoxified Staphylococcus toxin. The vaccine is injected into the skin and its effect is similar to that of a tetanus vaccination, says Jilma. "Immunization with such vaccines lasts for five years or more." Once vaccinated, a person develops antibodies, which become active if the germs start to pose a threat. A blood test can show whether someone is short of antibodies. Risk groups could then be preventively vaccinated.

"We are well on the way to having a vaccine that prevents this series disease. However, it will still take some years before it is in clinical use," explains Eibl. A Phase II trial with a larger test population has now started, in order to check the initial, promising results. "We are still looking for more volunteers," says Jilma.

Service: Lancet Infectious Diseases
"Safety, tolerability, and immunogenicity of a recombinant toxic shock syndrome toxin (rTSST)-1 variant vaccine: a randomised, double-blind, adjuvant-controlled, dose escalation first-in-man-trial." M. Schwameis, B. Rappenser, C. Firbas, C. Gruener, N. Model, N. Stich, A. Roetzer, N. Buchtele, B. Jilma, M. Eibl. Lancet Infectious Diseases, June 2016, dx.doi.org/10.1016.S1473-3099(16)30115-3

aripiprazole je najbolji lek trenutno da se ukontroliše delusional thinking, posebno kad je deluzija u kombinaciji sa emotivnom labilnošću. upravo dobih info da ga je moguće nabaviti i u srbiji.

Quote
Aripiprazole: A New Option in Delirium.
Prommer E¹.Delirium is a palliative care emergency where patients experience changes in perception, awareness, and behavior. Common features include changes in the sleep-wake cycle, emotional lability, delusional thinking, and language and thought disorders. Delirium results from neurotransmitter imbalances involving several neurotransmitters such as dopamine, glutamate, norepinephrine, acetylcholine, gamma-aminobutyric acid, and serotonin. Untreated delirium causes significant morbidity and mortality. Nonpharmacologic and pharmacologic approaches treat delirium. Current pharmacologic management of delirium involves using agents such as haloperidol or second-generation antipsychotics. Third-generation atypical antipsychotic drugs have emerged as a potential choice for delirium management. Aripiprazole is a third-generation antipsychotic with a dopamine receptor-binding profile distinct from other second-generation antipsychotics. Aripiprazole acts as partial agonist at dopamine D₂ and 5-hydroxytryptamine (5-HT)_1A receptors, stabilizing the dopamine receptor leading to improvement in symptoms. The article reviews the pharmacology, pharmacodynamics, metabolism, and evidence of clinical efficacy for this new antipsychotic agent.

Zanimljivo. Ali nama to ne treba sada kad imamo Kineze.

U drugim vestima:



Depressing paper suggests cancer's an evolutionary mechanism to 'autocorrect' our gene pool

QuoteTwo scientists have come up with a depressing new hypothesis that attempts to explain why cancer is so hard to stop.
Maybe, they suggest, cancer's not working against us. Maybe the disease is actually an evolutionary 'final checkpoint' that stops faulty DNA from being passed down to the next generation.
To be clear, this is just a hypothesis. It hasn't been tested experimentally, and, more importantly, no one is suggesting that anyone should die of cancer. In fact, it's quite the opposite - the researchers say that this line of thinking could help us to better understand the disease, and come up with more effective treatment strategies, like immunotherapy, even if a cure might not be possible.
So let's step back a second here, because why are our bodies trying to kill us? The idea behind the paper is based on the fact that, in the healthy body, there are a whole range of inbuilt safeguards, or 'checkpoints', that stop DNA mutations from being passed onto new cells.
One of the most important of these checkpoints is apoptosis, or programmed cell death. Whenever DNA is damaged and can't be fixed, cells are marked for apoptosis, and are quickly digested by the immune system - effectively 'swallowing' the problem. No mess, no fuss.
But the new hypothesis suggests that when apoptosis - and the other safeguards - don't work like they're supposed to, cancer just might be the final 'checkpoint' that steps in and gets rid of the rogue cells before their DNA can be passed on... by, uh, killing us, and removing our genetic material from the gene pool.
"Dividing cells have to be able to pass at least four crucially important checkpoints during different phases of the cell cycle," the researchers write in the paper, published in Biotechnology & Biotechnological Equipment.
Most of these four stages, like apoptosis, are checking for DNA damage, but they can occasionally miss things, and when they do, it can lead to uncontrolled cell growth, and eventually cancer. Unchecked, the researchers say, those DNA mutations could eventually be passed on - if the carrier isn't killed first.
It sounds like something out of a particularly brutal sci-fi plot, but the authors of the paper - Rumena Petkova and Stoyan Chakarov from the Scientific Technology Service and Sofia University in Bulgaria - defend their idea by explaining that old age is pretty much a similar mechanism. After all, the planet couldn't survive if we all lived forever.
"[Cancer] seems to be a key evolution mechanism similar to DNA repair and apoptosis that protects the life on Earth as we know it from being extinguished ... a kind of a supreme checkpoint to ensure replacement of generations and evolution on planet Earth," they explain.
What that means, they suggest, is that a "universal and radical" cure for cancer is unlikely to exist - but instead our best hope is to focus on finding ways to improve the lifespan and quality of life for those with the disease.
"Despite the successes of modern medicine, cancer is rarely completely cured and is likely to cause, directly or indirectly, the death of the patient," the authors write.
"Nevertheless, the medicine of today and the near future has enough potential to slow down the progression to terminal cancer so that the life expectancy and the quality of life of cancer-affected individuals may be comparable to those of healthy aged individuals."
That's obviously not an easy idea for anyone to swallow, particularly for those who are living with cancer themselves, or who have loved ones with the disease - but the good news is there's no evidence just yet to suggest that any of this is true.
Like we said before, it's just a hypothesis - and there are many out there - for why cancer has proven so challenging for modern medicine to halt. In the new paper, the researchers simply lay out scientific observations that support their hypothesis. It now needs to be tested experimentally to see if there's any evidence that it might be true.
But before we get to that point, there are already a few big holes, as Charlie Sorrel over at Fast Company points out, like the fact that cancer is more common as people get older, and therefore is most likely to kill them after reproductive age, when passing on genes is no longer an issue. 
"And if a cancer comes along to do it's clean-up after we've passed reproductive age, then it's too late to stop your defective genes from being passed along," writes Sorrel. "Not that gene heredity is that cut and dried, but, like the [hypothesis] presented here, it's an interesting thought experiment."
Ignoring cancer for a second, the bottom line of all this is really the fact that we were never meant to live forever, and the idea that our body has its own safeguards in place to make sure that doesn't happen. Whether or not that's true, it's probably time to get out there and start living, huh?
 

pa srce mi lomiš jer ne čitaš moje postove!

http://www.znaksagite.com/diskusije/index.php?topic=11875.msg639035#msg639035

Izvinjavam se, pročitao sam post, sećam se bugarskih imena, ali sam očigledno to zaboravio kada sam naleteo na ovaj članak. Kriv sam.

no need to be worried, imamo odličan a dostupan tretman a da nije u budućnosti!!

http://onlinelibrary.wiley.com/doi/10.1002/stem.277/full

Prelepo. Eh, što nisam miš...

jučerašnji dan je bio solidno uzbudljiv tako da sam noćas sanjala implante i bakterijski biofilm pa da podelim.

veštački kuk, veštačko koleno, i ostale androidne stvari koje će se možda naći u našim krhkim humanoidnim telima, sa sobom nose opasnost od bakterijske infekcije, al nije problem kad je u pitanju single infekcija već kad se bakterijice organizuju u biofilm a u biofilm se organizuju onda kad imaju odgovarajuću površinu na kojoj će da sviju gnezdo (idealno: naš veštački kuk! ).
čak i taj biofilm mi se do juče nije činio kao big problem al kad sam čula da se Staphylococcus aureus žrtvuje i umire for the sake of other towns, for the sake of humanity drugih bacterija prisutnih u biofilmu, shvatila sam da smo (we, the humans), na duže staze, ugasili.

šta radi s. aureus?
recimo: imamo s. aureus biofilm, e.g. bakterijski society na našem veštačkom kuku i rana neće da zaraste. rokamo se mi antibioticima, biofilm i tu ima ne preterano loša rešenja al kad rokamo najjačim oružjima, još uvek imamo šansu da se rešimo i biofilma (dok se ne sretnemo sa velikim brojem antibiotik rezistenstnih bakterija al to je za neku drugu priču).

u momentu kad biofilm (njegov površinski matrix) shvati da je celo društvo ugroženo, taj površinski deo kreće u programirani suicide da bi tako oslobodio ekstracelularnu DNK (eDNA) koja u velikom broju slučajeva spašava ostatak bakterijske družine. eDNA stabilizuje martrix biofilma, veže prisutne antibiotike, posreduje kod horizontalnog genskog transfera (pomoć za rezistenciju), krlja urođeni imunski odgovor tako što uglavnom sprečava fagocitozu a kad nema fagocitoze nema ni imunskog sistema protiv tih mikroba...

sve u svemu, ja fascinirana. in s. aureus we trust!

evo malo non-too-scientific-literature, kad nema šta pametnije da se radi:

http://www.podiatrytoday.com/what-you-should-know-about-biofilm-and-implants

https://microbewiki.kenyon.edu/index.php/Biofilms_and_Human_Implants

http://www.ncbi.nlm.nih.gov/pubmed/22094562

Dakle, veštački kukovi ima da dolaze sa već ugrađenim rezervoarima joda ili već nekog drugog oksidanta. Ništa drugo mi ne pada na pamet...

well, ne, jer tek onda nema šanse da rana zaraste.

ide se na razvoj lekova koji će da inhibiraju adheziju bakterija za implante, a radi se i na  novim neadhezivnim implant materijalima.

zanimljivo je i da su mehanizmi kojima biofilm operiše različiti u npr. kateterima i u veštačkom kolenu. onaj kateterski je uglavnom sastavljen od s. epidermidis i  cilj mu je da se što bolje prikači za kateter jer je svestan da mu života posle vađenja katetera nema a u kateteru ga ni imunski sistem ne ferma previše jer i on zna da će kateter da nas napusti jednog dana.
tako da tu osnovni mehanizam preživljavanja biofilma ide preko tzv. polisaharidnog intracelularnog adhezina (PIA) koji pojačava adheziju bakterija za kateter i omogućava formiranje biofilma.
ovi u kukićima morali su da razviju sofisticirane metode preživljavanja, eDNA je jedan takav.
ajd sve da prihvatim, al programirani suicide...e to me dirnulo!

autoimunske bolesti su solidan shit koji može da vas strefi u životu pošto vaš savršeni imunski sistem, a koji je naučen da fajtuje raznorazne izazove okoline, ne primeti i ne ubije klon koji se okrene protiv sopstvenog. onda taj klon (limfocit) krene da posmatra sopstveno kao strano (ljudsku ćeliju kao bakteriju, simplifikovano) i napravi čudo u organizmu.
za neke autoimunske bolesti relativno dobra terapija (medikamentima) postoji, za neke ne.
dugo sam radila u ovoj oblasti i znam s kojim problemima i izazovima se susreću ljudi koji su oboleli od širokog spektra ovih bolesti.
otud, jako lepe vesti:

QuoteImmune system autocorrect feature reverses autoimmune disease in mice

The human immune system—the powerful, complex network of cells that watches over and defends the body—just got a new weapon: autocorrect.

According to a report in Science, researchers were able to reverse an autoimmune disorder in mice by engineering certain healthy immune cells to weed out faulty ones. The method behind the treatment involves chimeric antigen receptor (CAR) T cells and is identical to the method used in an experimental therapy for certain types of leukemias and lymphomas that has so far proven successful in some small human trials. While researchers will need to do much more work to prove that the strategy holds up against autoimmune disorders in humans, the authors argue that its track record of beating cancers is reason to be optimistic.

"Our study effectively opens up the application of this anti-cancer technology to the treatment of a much wider range of diseases, including autoimmunity and transplant rejection," coauthor Michael C. Milone, of the University of Pennsylvania School of Medicine, said in a news release.

In those anti-cancer applications, engineered CAR T cells are used to fight off B cells that have become cancerous and are causing B cell-based leukemias or lymphomas. Normally, B cells are responsible for making antibodies, the Y-shaped proteins that detect germs and other invaders.

For the treatment, T cells are taken from a patient and genetically tweaked to contain an artificial detector—chimeric antigen receptor—that specifically singles out those cancerous B cells. Then researchers put the tweaked T cells back into the patient's blood, where they track down and destroy the bad B cells.

Milone and colleagues realized this strategy might work for certain types of autoimmune disorders, particularly ones involving rogue B cells. They decided to test out the idea on a rare autoimmune disease called pemphigus vulgaris. In patients with this disease, faulty B cells pump out antibodies that attack a protein that helps skin and membrane cells stick together. The result is painful blistering in various places on the body and in the mouth and throat. The disease can be fatal without treatments, which often include powerful, immune-suppressing drugs that leave patients defenseless against life-threatening infections.

In cell experiments and in mice engineered to have the disease, CAR T cells were able to take out the faulty B cells while leaving the rest of the immune system intact. The treated mice survived and no longer developed blisters.

Next, Milone and his colleagues will test out the therapy in dogs, one of the few other animals that naturally get the disease. If the strategy holds up, they'll move on to clinical trials and branch out to see what other autoimmune disorders CAR T cells might be able to treat.

T-limfocit je naravno lutka (elektronska mikroskopija)




ceo rad:
http://science.sciencemag.org/content/353/6295/179

A Medical Mystery of the Best Kind: Major Diseases Are in Decline

evolucija na delu?

Nešto je to mnogo brzo za ono kako evolucija inače radi...

hteo si da kažeš: ...za ono kako mi verujemo da evolucija inače radi?

kad sam već u the office (GB) modu, turiću ovo ovde:
http://xkcd.com/1706/

s tolkom glavudžom a ni procenat šarplaninca!

ajd da ne otvaram novu temu premda je naš imunski sistem fenomen na rubu SF-a, al oftopik volim više nego lebac 

dve lepe prezentacije: i) čime raspolažemo i ii) protiv kakvih kreatura se borimo:
http://www.inside-immunity.org/

http://antistresvodic.rs/seme-koje-sami-posadite-vas-najbolji-lekar/

QuoteSeme koje sami posadite
VAŠ NAJBOLJI LEKAR

Mame, tate, bake, deke, tetke, stričevi... svi vi koji sadite bašte ili pripremate rasade. Evo jednog divnog i korisnog odlomka iz knjige Anastasija, Vladimira Megrea, koju su na našem jeziku izdali Zvoneći kedri Srbije

Evo kako je govorila Anastasija o semenu posađenom vašom rukom, a zapisao Vladimir Megre:
– Svako, posađeno vašom rukom seme, sadrži u sebi ogroman obim Vaseljenske informacije. Ovaj obim se ne može porediti ni po veličini, ni po tačnosti, ni sa jednim veštačkim. Pomoću ove informacije seme zna tačno, do milionitog dela sekunde, vreme kada treba da se pokrene, počne da raste, kakve sokove da uzima iz zemlje, kako da koristi zračenja kosmičkih tela – Sunca, Meseca, zvezda, u šta da raste, kakve plodove da donosi. Plodovi su namenjeni obezbeđenju čovekovog života. Ovi plodovi mogu uspešnije i snažnije od veštačkih lekova, ranije stvorenih ili budućih, da se bore i suprotstave bilo kom oboljenju ljudskog organizma. Ali, o tome, o stanju čovekovom mora da zna seme, da bi se u procesu svoga zrenja zasitio plod neophodnim odnosom supstanci za lečenje određenog čoveka, njegovih bolesti ukoliko postoje, ili postoje predispozicije za njih.

Pre sadnje. Da bi seme krastavca, paradajza ili bilo kog drugog rastinja, uzgajano na parceli, imalo takvo obaveštenje, neophodno je sledeće:
– Pre sadnje uzeti u usta jedno ili nekoliko malenih zrna, držati ih u ustima pod jezikom, ne manje od devet minuta.
– Potom ih položiti između dlanova ruku i držati ih tako tridesetak sekundi. Među dlanovima svojim semenje držeći, treba stajati bos na tom komadu zemlje, na kom će se zatim odvijati sadnja.
– Otvoriti dlanove i seme koje leži u tvojim rukama pažljivo prineti usnama i izdahnuti na seme iz svojih pluća vazduh. Ugrejati ga dahom svojim, i to što postoji u tebi, maleno seme će upoznati.
– Onda je još nužno držati otvorene dlanove tridesetak sekundi, nebeskim telima seme predstavljajući. I seme će ustanoviti trenutak svog izlaska. Planete sve će mu pomoći u tome! I za tebe će izdancima potrebnu svetlost darivati.

Zalivanje posle tri dana. Anastasija kaže da se seme nakon toga može u zemlju posaditi.
– Ni u kom slučaju ga ne treba odmah zalivati, da se ne bi sprala pljuvačka koja je obavila seme, i obaveštenje o tebi koje seme u sebe upija. Po isteku tri dana od sadnje, dozvoljeno je zalivanje.
Sadnju je neophodno sprovoditi u pogodnim danima za određeno povrće (to je svakom čoveku već poznato po mesečevom kalendaru). Ranija sadnja bez zalivanja nije tako strašna, kao prekasna.
– Ne treba spaljivati pored sadnica sav korov koji se pojavio. Treba od raznih vrsta ostaviti bar po jedan. Korov se može podrezati...

Plodovi koji su naš lek. Po rečima Anastasijinim, seme na ovaj način upija u sebe obaveštenje o čoveku, i u toku sazrevanja svog ploda do maksimuma će odabirati iz kosmosa i zemlje neophodnu energiju, upravo za tog određenog čoveka. Korov sav ne treba ukloniti zato, što i on ima svoje predodređenje. Jedan štiti biljke od bolesti, drugi daje dodatne informacije. U vreme rasta, treba dolaziti u dodir sa biljkama – barem jednom u toku njihovog sazrevanja. Poželjno je u vreme punog Meseca prilaziti im i dotaći ih.
Anastasija je tvrdila da su plodovi, uzgajani na ovaj način, ako ih upotrebljava čovek koji ih je sam negovao, kadri da ga izleče od apsolutno svih bolesti, da znatno usporavaju starenje organizma, oslobađajući ga od loših navika, da mnogo puta uveličavaju radne sposobnosti, dajući duševni mir. Plodovi će imati najdelotvorniji uticaj ukoliko se upotrebe najkasnije tri dana od branja.

Razlika ne samo u izgledu. Nije obavezno saditi na taj način cele leje. Dovoljno je da bude po nekoliko strukova.
Uzgajani na ovaj način, plodovi će se razlikovati od drugih iste sorte, ne samo po ukusu. Ukoliko se podvrgnu analizi, razlikovaće se i po odnosu supstanci u njima. Odnosi će biti potpuno različiti.
Pri polaganju sadnica obavezno je svojim rukama i prstima bosih nogu izgnječiti zemlju i pljunuti u rupu. Na pitanje, zbog čega nogama – Anastasija je pojasnila da kroz znojenje nogu iz čoveka izlaze supstance (verovatno toksini), koje sadrže obaveštenje o bolestima organizma. Tu vest će dobiti mladice. One će je preneti plodovima, koji će onda biti u stanju da se bore sa nedaćama. Anastasija je savetovala da se s vremena na vreme po parceli hoda bos.

Kakve kulture je neophodno gajiti. Anastasija je na ovo konkretno pitanje odgovarala da treba da ih bude onoliko raznorodnih koliko postoji na većini parcela: maline, ribizle, ogrozd, krastavci, paradajz, šumske jagode, bilo koja jabuka. Veoma je dobro ako postoji višnja ili trešnja, cveće. Količina, veličina parcele koja se sadi ovim kulturama, nema neki veći značaj.
Kao obavezne, bez kojih je teško zamisliti pun energetski mikroklimat, na parceli treba uvrstiti takvo rastinje kao što je suncokret (barem jedan). Neizostavno treba posejati na parceli, veličine jedan i po do dva kvadratna metra, žitne kulture – raž, pšenicu, i obavezno ostaviti ostrvce, ne manje od dva kvadratna metra, pod različitom travom. To se ostrvce ne sme sejati veštački, treba da bude prirodno. Ukoliko niste sačuvali na svojoj parceli razne trave, treba doneti iz šume busen i stvoriti takvo ostrvce uz njegovu pomoć.

Prirodni lekar. Vladimir Megre je pitao Anastasiju ima li potrebe za sadnjom kultura, koje ona smatra obaveznim, ukoliko iza ograde, nedaleko od parcele, one već postoje. Dobio je sledeći odgovor:
– Važnost ima ne samo raznovrsnost, već i način njihove sadnje, neposredno opštenje s njima, preko kog se i odvija zasićivanje obaveštenjima. Već sam ti govorila o jednom od načina sadnje – on je osnovni. Najvažnije je – zasititi obližnji deo prirode vestima o sebi. Samo je tada lekovit učinak, te će čak i imunitet tvog organizma biti znatno uvećan. Mnogo više nego od uobičajenih plodova. U divljoj, kako je vi nazivate, prirodi, a ona nije divlja, već vam je prosto nepoznata, postoji mnoštvo biljaka, uz čiju se pomoć mogu izlečiti apsolutno sve postojeće bolesti. Te biljke su zato i stvorene, ali je čovek izgubio, ili skoro sasvim izgubio sposobnost da ih prepozna.
Ispričao sam Anastasiji da kod nas postoji mnogo specijalizovanih apoteka koje trguju lekovitim travama, ima i lekara, i vidara, koji leče travama profesionalno, na šta je ona odgovorila:
– Postoji glavni lekar – tvoj organizam. On je odvajkada obdaren sposobnošću da zna, koju travu je neophodno upotrebiti i kada. Kako se uopšte hraniti, disati. On je u stanju da predupredi bolest, pre njenih spoljašnjih znakova. I niko drugi ne može da zameni tvoj organizam, jer je to tvoj lični lekar, dat lično tebi, isključivo tebi, od Boga. Objašnjavam ti kako da mu daš mogućnost da deluje u tvoju korist.
Uređeni uzajamni odnosi sa skupom bilja na tvojoj parceli lečiće te i brinuti o tebi. Samostalno će postaviti tačnu dijagnozu, i pripremiti poseban, najdelotvorniji, upravo za tebe, lek.

http://www.svevlad.org.rs/narodni_zivot_files/narodna_medicina.html
http://www.novosti.rs/vesti/naslovna/reportaze/aktuelno.293.html:229749-Bajalice-lece-dusu
http://www.glas-javnosti.rs/clanak/glas-javnosti-19-11-2007/da-ti-bajam-da-t-izlecim
Nema, brale, di zerbiše medicina je di beste medicina. 

Лековима фармакомафије се нико није излечио, већ су људи претворени у таблетомане који, да би живели, морају свакоднедневно да гутају таблете које одржавају у функцији оболели орган.
Тако популација постаје зависна од произвођача лекова.

Сећам се времена кад људи нису гутали никакве таблете, живели су колико толико у складу са приородом и доживљавали дубоку старост.
Док су Срби гутали глог и дрен да имају здраво срце и да буду здрави ко дренови - нису гутали таблете.

Шта је са применом индустријске конопље?
Алескијев Тито је Србима забранио конопљу, од чије би производње Србија, као превасходно пољопривредна земља, могла да процвета, што због експеримената у области медицине (уље против рака, мелеми за опекотине итд итд), што због свих могућих продуката на произведених на бази конопљиног влакна, попут одеће, обуће, блокова за градњу кућа од конопље, плус би било довољно хране произведене од семенки конопље.
Просто речено, биљка створена од Бога да голог обуче, да оном без куће створи кров над главом, да болесне лечи и да гладне нахрани високопротеинском и омега мастима здравом храном.

Значи, линк који сам пре неки дан поставио има везе са лечењем помоћу биљака, и лично сведочим да семе третирано на начин описан у тексту који сам поставио даје крупнији цвет са много више латица од семена које није третирано на такав начин.

На даље, помињеш бајалице.
Не видим ништа спорно у лечењу бајалицама, јер не треба потцењивати моћ изговорене речи.

Такође, будућност не лежи у таблетама и медицинским киборг причама, већ будућност лежи у биоенергији, самоисцеливању и саморегенерацији оболелих органа, но за тако нешто је потребан и одређен ниво више свести, јер је теорија биг бенга убедила наивне да су продукт случајности, а теорија еволуције је на то надодала да су продукт и еволуцијске случајности, па такав наивко који је прогутао те приче о случајним случајностима себе не доживљава као део Свемира већ као апгрејдованог мајмуна, па никад неће ни помислити да поседује нпр. биоенергију, а о телепатији или телекинези да не говоримо...

Као што сам рекао, биоенергија представља једну од грана будуће медицине ослобођене од фармакомафије, таблета, капсула и других ствари које не лече него залечују и човека чине робом своје болести.
Охрабрујем свакога да ствар преузме у своје руке и да почне са спознајом себе.

QuoteBioenergija je energija zivota, doslovno "zivotna energija". Lecenje uz pomoc bioenergije je terapija koja moze uravnoteziti i uskladiti fizicko i duhovno stanje organizma. Ovakva terapija usmerena je na bioenergetska polja, energetske centre i kanale po kojima energija tece u telu. Da pokusamo da pojasnimo, svaka stanica u ljudskom telu funkcionise uz pomoc energije, emitirajuci elektricne impulse, sto zauzvrat cini elektro-magnetno bio-energetsko polje koje okruzuje nasa tela.

http://www.priroda-leci-sve.com/bioenergija.htm

Naučne teorije su upravo to zbog čega imam pojačan osećaj da sam deo veće celine. Svi atomi teži od helijuma su nastali eksplozijom zvezda. U nama je zvezdana prašina. Većinu našeg genoma smo nasledili iz davnina i sastavni smo deo biosfere. Naš predak nije došao na gotovo, nego se izborio za svoj deo Zemlje. Sve je to davno utvrđeno, pre nego što su se naši dedovi i rodili. Nema tu nikakve sumnje.

Ali hajde, igramo se, reci dakle u šta tačno sumnjaš, i naučni razlog zbog kojeg sumnjaš. Sumnja je zdrava, ali u nauci imamo sistem. Ako postoje dokazi za tvrdnju onda te dokaze moraš da opovrgneš, a ne tvrdnju. Tvrdnja je samo posledica dokaza. Navedi dokaz i navedi zašto taj dokaz tebi nije dobar.

Konoplja je zabranjena u SAD negde 1947-48 posebnim zakonom jer ima u sebi THC. Međutim, pravi razlog zabrane konoplje (ne sve, industgrijksa nije kod nas zabranjena ali je fabrike koje bi prerađivale ne postoje) počiva u tome što je jak lobi vlasnika šuma tražio da se zabrani ovaj OBNOVLJIVI izvor celuloze od koje pravio papir i tkanina, kako bi iskoristili šumska bogastva koja su posedovali.
Kada bi konoplju upotrebljavli za odeću, farmerke ili jakne, one bi trajale i po 40 godina. Papir ne bi bio problem, šume ne bi bile sečene itd.
A i T2 bi mogao da razmišlja u hladu konopljinog lista o tom njegovom imaginarnom četničkom komunizmu.

Crispr: Chinese scientists to pioneer gene-editing trial on humans

Quote
A team of Chinese scientists will be the first in the world to apply the revolutionary gene-editing technique known as Crispr on human subjects.

Led by Lu You, an oncologist at Sichuan University's West China hospital in Chengdu, China, the team plan to start testing cells modified with Crispr on patients with lung cancer in August, according to the journal Nature.
Crispr is a game-changer in bioscience; a groundbreaking technique which can find, cut out and replace specific parts of DNA using a specially programmed enzyme named Cas9. Its ramifications are next to endless, from changing the color of mouse fur to designing malaria-free mosquitoes and pest-resistant crops to correcting a wide swath of genetic diseases like sickle-cell anaemia in humans.
The concept of editing human DNA has often been controversial. In the UK, genetic modification in humans remains off-limits. Peter Mills, assistant director of the UK Nuffield Council on Bioethics, has told the Guardian of the worries it raises about playing god and "designer babies".

A study on non-viable human embryos, also conducted in China, was called off after researchers found what they described as "serious obstacles" to using the method in a clinical setting.



And in March 2015 a group of researchers published an open letter in Nature saying that there were "grave concerns" about the ethical and safety implications of editing the "germ-line" in human genes – the genetic code which is passed on.


The Sichuan University trial, it is important to note, does not edit the germ-line; its effects will not be hereditary.
What the researchers plan to do is enroll patients with metastatic non-small cell lung cancer, Nature reported, and for whom other treatment options – including chemotherapy and radiotherapy – have failed.
They will then extract immune cells from the patients' blood and use Crispr to add a new genetic sequence which will help the patient's immune system target and destroy the cancer. The cells will then be re-introduced into the patients' bloodstream.
China has been at the forefront of Crispr research. In 2014, researchers at Nanjing University reported that they had successfully engineered mutations in macaques – the first reported successful use of the technique in non-human primates.
Crispr was approved for human trials in the US by a research group backed by tech billionaire Sean Parker, but if it begins on schedule in August the Sichuan University study will beat them to the punch of being the first of its kind.

Склапао је Тито и дил са америма за памук, зато нам је конопља забрањена, иначе све речне обале су биле под конопљом.
Пре неки дан сам видео кошуљу од конопље стару 90ак година, време се на њој уопште не познаје.

@mac
Кажеш: ali u nauci imamo sistem.

Какав си ти научник, и какав си ти део било каквог научног система?
Осим ако евентуални рад у просвети не сматраш битним фактором, мислим просветари су јако битни и они штрајкују само онда када им зине дупе за паре а никако да се сете да штрајкују због лошег образовног система којим заглупљују децу.

Šta sad, ja sam kriv za nešto? Za šta sam tačno ja kriv?

I koji dokaz bi želeo da opovrgneš?

Крив си јер у оквиру своје радне заједнице не подстрекаваш колеге на штрајк због неадекватног образовног програма са којим свакодневно радите и чијем погубном дејству излажете генерације младих Срба.
Крив си јер по форуму пишеш о револуцији, а у оквиру своје радне заједнице не позиваш ни да се штрајкује.

Дај ми доказ да хемотерапија успешно лечи рак.

Ima dokaza, naravno, pa nisu osiguravajuća društva veverice, pa da plaćaju za nešto što ne daje rezultate. Follow the money. Ali nije na meni da dokazujem nešto što je odavno utvrđeno, nego na tebi da dokažeš novu tvrdnju. Tvoja tvrdnja je novum, koji pobija ono što je ustanovljeno, znači obaveza je na tebi. Nije dovoljno samo da kažeš "ja ne verujem u hemoterapiju", potrebno je nešto jače, tipa "u poslednjih godnu dana hemoterapiju je primilo x pacijenata, projektovano izlečenje je bilo y%, a zapravo izlečenih je z%, i to z je toliko malo da ne opravdava hemoterapiju kao vid borbe protiv kancera". E to je iskaz, i kad bi rekao tako nešto, i kad bi to još bila i istina, ispao bi ljudina i čestit čovek.

Ima ovde detaljna rasprava o ovom pitanju:



Chemotherapy doesn't work? Not so fast...

Ниси ми дао ниједан доказ да нешто што је направљено од заосталих нервих агенаса из другог светског рата може да излечи рак.

Да је заиста тако - не би људи ишли чак у Албанију да наточе кило петролеја којим се лече, или скупљају последњу цркавицу да им се из иностранства донесе уље од конопље.

Какв исказ, какви проценти, ти бараташ шатро бројкама, ја радим са живим људима, и свакодневно се умире од рака, проценат излечених помоћу хемотерапије је НУЛА.

Крив си јер подржаваш постојеће стање и кријеш се иза лажнних статистичких показатеља (ко несрећници у 1984) доводећи у заблуду друге којима си окружен да је све у најбољем реду.

Šta radiš sa živim ljudima? Radiš u osiguravajućem društvu, ili kao doktor u domu zdravlja, ili si konobar/taksista/novinar/policajac? Koje su ti kvalifikacije za procenu efektivnosti dejstva hemoterapije, osim što su ljudi s kojima radiš živi?

Budi čovek, teži znanju, beži od neosnovanih izjava, poput one da se poznati Kelti mogu zvati samo Bran...

Da, to za petrolej i ulje od konoplje su nezgodne stvari. Ljudi troše ozbiljne pare na nešto što ne leči*, ali, eto, nada umire poslednja valjda.... Ja sam letos sahranio taštu koja je sve to probala, pa eto - sahranjena je. Doduše, nije je ubio rak na kraju, već embolija koja je došla kao posledica transfuzije krvi a koja joj je bila neophodna jer joj je bolest jako oslabila krvnu sliku itd... U svakom slučaju, ulje od konoplje tu nije bilo ni od kakve pomoći, pa ako su individualne priče argumenti, eto jednog...











* bar ne postoje proverljivi dokazi da leči

kad bi hemoterapija stvarno bila krivac, a ne placebo i razni eksperimentalni lijekovi koje nam podmeću, a koji nigdje nisu ranije isprobani

zato se ''elita'' i ne liječi na Balkanu nego Pariz-Njujork i te fore, a ovdje uvezu sranje od lijekova, čija je učinkovitost znatno manja

Quote from: Meho Krljic on 25-07-2016, 08:47:08
Crispr: Chinese scientists to pioneer gene-editing trial on humans

ej mehane, super da si stavio ovaj trial (premda se neće ići dalje od faze 1, znači samo safety and tolerability, i na jednom pacijentu dodatno definisanje doze) jer shvatih da dosad nismo pominjali crispr/cas9 sistem za editovanje DNK a to je big otkriće 21. veka sa velikim potencijalom za tretiranje genetskih bolesti ali i kancera, dijabetesa i sl.

http://www.youtube.com/watch?v=2pp17E4E-O8

gud njuz, taman će je napraviti kad budem ready za penziju

QuoteFluGen Starts Clinical Trial for Universal Flu Vaccine

It took longer than FluGen planned, but a human clinical trial is now underway for the experimental universal influenza vaccine that the Madison, WI-based biotech startup is developing.

The primary goals of the trial announced Wednesday are to evaluate the safety of the vaccine, which is known as Redee Flu, and evaluate antibody and T-cell responses in study participants, the company said.

Ninety-six subjects, all between the ages of 18 and 49, will be dosed with the vaccine, FluGen said. They are broken into three groups of 32, and the dosage will increase with each group, said Paul Radspinner, FluGen's co-founder, president, and CEO.

"We've already started dosing subjects in the first cohort," Radspinner said in an interview. "Once we clear the first week of this group, then we'll start recruiting for the second group."

Radspinner said that researchers will be taking measurements on subjects throughout the study, but investigators must wait 28 days after a cohort has been dosed before they can collect the most vital data on subjects' immune responses.

FluGen leaders hope to have safety and immune response data on all three cohorts in the trial by December, Radspinner said.

One benefit of a universal flu vaccine is that it could protect against strains of the virus that vary from the ones groups like the CDC and World Health Organization predict will be the predominant strain (or strains) for a given flu season.

Redee Flu is made up of a live flu virus from which a key gene, known as M2, has been deleted. The vaccine virus is able to live in the body just long enough to provoke a strong immune response, but thanks to the deleted gene it's not able to cause disease or spread to other people, according to FluGen. Radspinner said that other companies, such as Fort Collins, CO-based Vivaldi Biosciences, are developing vaccines that have similarities to Redee Flu, but that he does not know of any that remove the M2 gene.

Radspinner said that after the current clinical trial concludes, FluGen is likely to initiate a Phase 1b trial. The goal is for that to happen sometime in 2017, he said. The company also plans to conduct a challenge study in which subjects would receive a vaccine designed to primarily protect against a particular flu strain, then be "challenged" by being dosed with a different strain of the virus. The idea is to test a vaccine's ability to protect against "drifted or mismatched flu strains," as FluGen termed them in a press release.

"It would mimic what happened in 2014 and 2015 when there was a mismatch between the vaccine and the prevailing strain," Radspinner said.

FluGen has raised a total of about $20 million from investors, Radspinner said, and the company is in the process of securing additional capital commitments. He co-founded FluGen in 2007, along with Yoshihiro Kawaoka and Gabriele Neumann.

At the time FluGen closed a $3.4 million bridge financing round in June 2014, the plan was to get a vaccine into human trials in early 2015. FluGen was still working toward that goal when it raised another $9.4 million in August 2015.

Radspinner said there are a few reasons for the delay between then and now. Among them were completing preclinical studies and a FDA Good Laboratory Practice study, as well as making sure the vaccine material was manufactured in a way that meets standard FDA specifications, he said.

"And then finally, probably the most important thing was to put together the [investigational new drug] document that had to be given to the FDA," Radspinner said. "Obviously, we had to succeed with that in order to initiate this study."

taman da se pobije bapska priča (ili potvrdi, ko će ga znati): stalno spominju kako je nemoguće da ova regionalna ministarstva zdravlja znaju baš koji će tip gripa da navali, i baš tu vakcinu naruče te zime.

Naravno, teorija zavjere tvrdi da to neki tvoji zli laboranti ubace međ pošten svijet, dok razumnije objašnjenje jeste da se prati epidemija globalno i da se može prognozirati širenje. Samim tim se prilično pouzdano može znati koju vakcinu treba kupiti

pitanje je, dakle, da li babe griješe?

kakva bre regionalna ministarstva, oni naručuju ono što se za tu godinu proizvede a proizvodnja kreće u februaru najkasnije na osnovu preporuka epidemioloških studija za tu godinu (u australiji je zima kad je kod nas leto, da simplifikujem  )

Quotehttp://www.who.int/influenza/surveillance_monitoring/en/

The WHO's Global Influenza Programme (GIP) provides global standards for influenza surveillance. In addition GIP collects and analyzes virological and epidemiological influenza surveillance data from around the world. The regular sharing of quality influenza surveillance and monitoring data by countries allows WHO to:

  -  provide countries, areas and territories with information about influenza transmission in other parts of the world to allow national policy makers to better prepare for upcoming   
seasons;
  -  describe critical features of influenza epidemiology including risk groups, transmission characteristics, and impact;
  -  monitor global trends in influenza transmission; and
   - support the selection of influenza strains for vaccine production.

plus

QuoteThe ability to identify new strains of influenza viruses and describe their circulation has expanded in recent years. National virologic data are obtained through weekly reports from ∼75 World Health Organization (WHO) and 50 National Respiratory and Enteric Virus Surveillance System laboratories. Global viral surveillance involves 115 national influenza centers in 84 countries that analyze 175,000–200,000 samples and characterize 4000–8000 viruses annually. Viruses submitted for detailed antigenic and genetic characterization to WHO centers in Atlanta, London, Melbourne, and Tokyo are used in formulating annual influenza vaccines [4]. A recent initiative to strengthen the influenza surveillance infrastructure in Asia and elsewhere is expected to lead to enhanced viral surveillance and to provide a better early-warning system for viruses with pandemic potential [5]

pošto sam već u ofisu, još jedna gud njuz: napokon se krenulo sa long-acting lekom protiv šizofrenije (paliperidone palmitate ) - 4x godišnje - injekcija - nema zaboravljanja ili izbegavanja terapije.

QuoteLong-acting schizophrenia drug could reduce relapses

The approval of a new, very long-acting schizophrenia medication by Health Canada could encourage more patients to use injectable drugs that reduce relapses, according to a leading psychiatrist.

"Patients who are reluctant to be injected every two weeks or every four weeks would only have to take this drug once a season," said Howard Margolese, a Montreal-based expert in the treatment of schizophrenia. "That increases acceptability of this form of treatment because it is less often and less invasive."

Invega Trinza — paliperidone palmitate — is injected four times a year by a physician or a nurse. Previously approved injectable medications for schizophrenia are typically injected at least once a month, while oral medications are taken at least once a day, 365 days a year.

"People who respond well to (long-acting) medications don't have to feel like a patient between visits, they don't have to remember to take medication every day and they can focus on other goals and other aspects of their lives," said Margolese.

Schizophrenia is a complex mental illness characterized by abnormal social behaviour, delusion and hallucinations that affects 40,000 British Columbians and 350,000 Canadians. About 80 per cent of people with schizophrenia suffer a relapse in the first five years of treatment.

An analysis of five drug-compliance studies published by the Journal of Clinical Psychiatry found that only half of patients with schizophrenia take their oral medication at least 75 per cent of the time.

Patients taking long-acting injectable medications are far less likely to relapse, which reduces the rate and duration of hospital stays particularly in patients who struggle to take daily oral medication consistently, he said.

"For a lot of patients, their symptoms interfere with their ability to take medication reliably," said Chris Summerville, CEO of the Schizophrenia Society of Canada. "With a mental illness, it is critical that you take medication regularly."

Patients and their families are eager for solutions, he said. There is also a strong economic case for long-acting drugs.

So-called "mirror studies" that follow patients before and after switching from daily oral medication to long-acting injectable medication show a significant reduction in hospitalizations in patients taking long-acting drugs, according to a meta-analysis of 25 studies involving 5,940 patients published in the Journal of Clinical Psychiatry.

A Canadian mirror study by Fiore Lalla and Larry Arshoff of long-acting medications involving just 19 patients who were heavy users of emergency and in-patient services noted savings of more than $1 million in hospitalization costs in one year.

Randomized control trials comparing oral and injectable medications have failed to show a difference in relapse rates, but those studies set a high bar for inclusion that would disqualify unstable patients who don't take their medication reliably, the very people injectable meds help the most, said Margolese.

In addition to reducing hospitalization rates, longer-acting drugs may allow some patients to go longer between appointments with their psychiatrist, he said.

"The main difference with injectable drugs is that we know when patients aren't taking it and that gives us a chance to do something about it," said Margolese. "With oral medications, we simply don't know if patients are taking them."

A clinical trial found that nine per cent of patients taking Invega Trinza relapsed, compared with 29 per cent of patients taking a placebo.

http://www.calgaryherald.com/health/long+acting+schizophrenia+drug+could+reduce+relapses/12074257/story.html

NIH moves to lift moratorium on animal-human chimera research

Quote
The National Institutes of Health (NIH) today announced that the agency soon expects to lift a moratorium on funding for controversial experiments that add human stem cells to animal embryos, creating an organism that is part animal, part human. Instead, these so-called chimera studies will undergo an extra layer of ethical review but may ultimately be allowed to proceed.
Although scientists who support such research welcomed the move, some were left trying to parse exactly what the draft policy will mean. It is "a step in the right direction," says Sean Wu, a stem cell researcher at Stanford University in Palo Alto, California, who co-authored a letter to Science last year opposing the moratorium. But "we still don't know what the outcome will be case by case," he adds. However, some see the proposal as opening up research in some areas that had been potentially off-limits.
At issue are experiments in which scientists introduce human pluripotent stem cells—cells that can potentially turn into any kind of tissue—into very early embryos of mice and other animals and then let the animals develop. Such experiments can be used to study human development, generate disease models, and potentially grow human organs for transplantation. But the idea of such human-animal chimeras has drawn public concern, and some scientists and ethicists worry that the experiments could produce, say, a supersmart mouse.
Last September, NIH abruptly announced it was suspending funding for studies that introduce human stem cells into animal embryos while the agency considered the ethical issues. Although NIH wasn't yet funding such research, the pause put on hold future federal support for studies by researchers who want to create pig-human or sheep-human chimeras to generate organs for transplantation. NIH then held a workshop last November to gather input, where the general consensus was that these studies are scientifically valuable.
According to two notices released today, NIH is proposing to replace the moratorium with a new agency review process for certain chimera experiments. One type involves adding human stem cells to nonhuman vertebrate embryos through the gastrulation stage, when an embryo develops three distinct layers of cells that then give rise to different tissues and organs. The other category is studies that introduce human cells into the brains of postgastrulation mammals (except rodent studies, which won't need extra review).
These proposed studies will go to an internal NIH steering committee of scientists, ethicists, and animal welfare experts that will consider factors such as the type of human cells, where they may wind up in the animal, and how the cells might change the animal's behavior or appearance. The committee's conclusions will then help NIH's institutes decide whether to fund projects that have passed scientific peer review.
NIH also wants to tighten its existing stem cell guidelines to prohibit studies that add human stem cells to primate embryos up to and including the blastocyst stage. (Current guidelines only prohibit adding human pluripotent cells to primate blastocysts.) And the agency wants to extend a current ban on breeding chimeric animals that might carry human eggs or sperm to include chimeras created with any kind of human cell, not just pluripotent stem cells.
"I am confident that these proposed changes will enable the NIH research community to move this promising area of science forward in a responsible manner," writes NIH's associate director for science policy Carrie Wolinetz in a blog post today. In a call with reporters, she emphasized that the proposal "is not ... a prohibition" on chimera research. "It is merely an extra look."
NIH is collecting comments on the proposed changes until 4 September, then hopes to issue a final policy and lift the moratorium by late January, Wolinetz said.
Although some scientists are holding their applause, one sees the proposed policy as an indication that NIH is relaxing its chimera policy. Neuroscientist Steve Goldman of the University of Rochester in New York, who injects human stem cells into the brains of mice, notes that even experiments that put human cells into the brains of monkeys or other primates appear to be potentially permissible. Such studies, which could be useful for studying mental illnesses, "had been a very murky zone" until now, Goldman says. The proposed changes suggest "a much more permissive environment."

 Measles are gone from the Americas 

Quote
The Americas are now free of measles and we have vaccines to thank, the Pan American Health Organization said earlier this week.
This is the first region in the world to be declared measles-free, despite longtime efforts to eliminate the disease entirely. The condition — which causes flu-like symptoms and a blotchy rash — is one of the world's most infectious diseases. It's transmitted by airborne particles or direct contact with someone who has the disease and is highly contagious, especially among small children.
To be clear, there are still people with measles in the Americas, but the only cases develop from strains picked up overseas. Still, the numbers are going down: in the US this year, there have been 54 cases, down from 667 two years ago. The last case of measles that developed in the Americas was in 2002. (It took such a long time to declare the region measles-free because of various bureaucratic issues.)
Health officials say that credit for this victory goes to efforts to vaccinate against the disease. Though the measles, mumps, and rubella (MMR) vaccine is recommended for all children and required by many states, anti-vaxxers have protested it due to since-discredited claims that vaccines can cause autism.
   To stop transmission, 90 to 95 percent of people in a given region need to be vaccinated according to Seth Berkley, who runs the nonprofit GAVI, which promotes vaccination and immunization. In the US, that number is around 90 percent, but worldwide the number is only about 80 percent. Though declaring the Americas free of measles is a big step, people should keep vaccinating to ensure the disease doesn't come back, experts say.

ma dobro, ovo je malo PR-a al lepo je da se brojke spuštaju.

Quote
Innate Immunity and Asthma Risk in Amish and Hutterite Farm ChildrenMany genetic risk factors have been reported to modify susceptibility to asthma and allergy, but the dramatic increase in the prevalence of these conditions in westernized countries in the past half-century suggests that the environment also plays a critical role. The importance of environmental exposures in the development of asthma is most exquisitely illustrated by epidemiologic studies conducted in Central Europe that show significant protection from asthma and allergic disease in children raised on traditional dairy farms. In particular, children's contact with farm animals and the associated high microbial exposures have been related to the reduced risk. However, the effect of these traditional farming environments on immune responses is not well defined.
To address this gap in knowledge, we designed a study that compares two distinctive U.S. farming populations — the Amish of Indiana and the Hutterites of South Dakota — that recapitulate the differences in the prevalences of asthma and allergy observed in farmers and nonfarmers in Europe. These two particular groups of farmers originated in Europe — the Amish in Switzerland and the Hutterites in South Tyrol — during the Protestant Reformation and then emigrated to the United States in the 1700s and 1800s, respectively. Both groups have since remained reproductively isolated. Their lifestyles are similar with respect to most of the factors known to influence the risk of asthma, including large sibship size, high rates of childhood vaccination, diets rich in fat, salt, and raw milk, low rates of childhood obesity, long durations of breast-feeding, minimal exposure to tobacco smoke and air pollution, and taboos against indoor pets. However, whereas the Amish practice traditional farming, live on single-family dairy farms, and use horses for fieldwork and transportation, the Hutterites live on large, highly industrialized, communal farms. Strikingly, the prevalence of asthma in Amish versus Hutterite schoolchildren is 5.2% versus 21.3% and the prevalence of allergic sensitization is 7.2% versus 33.3%, as previously reported.

mnogo lepa studija kojom su dokazali ulogu okoline na razvoj urođene imunosti (innate immunity) plus kad tu vrstu imunosti lepo stimulišemo i razvijemo, imamo i manje astme međ đecom (sve smo mi to naravno znali i ranije i primenjivali staru narodnu: pusti đecu u prašinu i daj im da jedu s poda, al ne daj da se valjaju u barama  )

šalu na stranu, imamo dve etno-religijske grupe: amiše i huterite (https://en.wikipedia.org/wiki/Hutterite), zavidne genetske sličnosti (što je bitno za isključenje genetske komponente u ovoj studiji), relativno izolovane zajednice, osnovna razlika je u tome što amiši sve rade bez struje (npr. konje koriste za obradu zemlje) a huteriti se ne gade struje, pa zemlju obrađuju mašinski.
u svakom slučaju, zaključak studije je da bakterije prisutne u amiš kućama imaju molekul koji deluje protektivno na razvoj određenih delova urođene imunosti, a bakterijice u kućama huterita nemaju te karakteristike (malo pojednostavljeno).

e sad, terapija neće biti isključenje struje svima već dalja karakterizacija prašine u amiša, identifikacija protektivnih bakterija i njihovih produkata, pa možda svi mi alergičari konačno odahnemo!
sve ovo je na dugačkom štapu al bitno je da se palamudi.

evo studijica:
http://www.nejm.org/doi/full/10.1056/NEJMoa1508749#t=article

a evo i filmić. i moja mama razumela temu. 
http://www.nejm.org/do/10.1056/NEJMdo005078/full/?requestType=popUp&relatedArticle=10.1056/NEJMoa1508749

Ako mogu tu prašinu da stave u pilulu, da se daje deci, to će biti pun pogodak 

ja predložila da povremeno razmene decu na nekoliko meseci al su mi objasnili da to i nije tako veličanstvena ideja. 

da, da, pilula (mukoza oralno, jedini problem što ide u želudac gde se isecka i što treba i što ne treba) ili još bolje sprej (mukoza intranazalno ili konjunktivalno) bi bio pravi pogodak!

jutros malo EPP-a za "firmu".

uvetis (https://sh.wikipedia.org/wiki/Uveitis) je solidno dosadna i gadna boleščina posebno što može da odvede do trajnog slepila. može biti posledica raznoraznih infekcija (virusi, bakterije, gljivice, paraziti) ili sekundarna manifestacija nekih sistemskih bolesti. povrede oka takođe mogu da dovedu do uveitisa a i autoimunska etiologija (ono kad se naš imunski sistem bori protiv nas samih) nije isključena.

elem, upravo je objavljena studija da ćemo, odsad pa nadalje i ubuduće, umesto lekova na bazi kortizona (širok spektar nus efekata, npr: https://www.psychologytoday.com/blog/the-athletes-way/201301/cortisol-why-the-stress-hormone-is-public-enemy-no-1), za tretman neinfektivnog uveitisa moći da koristimo Adalimumab (https://en.wikipedia.org/wiki/Adalimumab). radi se o leku koji je praktično humani imunoglobulin  (tj. monoklonsko antitelo koje se vezuje za TNFa koji je medijator upale i inhibira je) koji već koristimo za tretman nekih drugih autoimunskih bolesti.

Quote
Cortisol-free rheumatoid arthritis medication also works for rare eye disease Summary:A well-known rheumatoid arthritis medication containing the active agent adalimumab, a therapeutic human monoclonal antibody, is also effective for treating non-infectious uveitis, a rare eye disease, report scientists.

---

A well-known rheumatoid arthritis medication containing the active agent adalimumab, a therapeutic human monoclonal antibody, is also effective for treating non-infectious uveitis, a rare eye disease. This has now been discovered by an international research group, in which MedUni Vienna was also involved with significant participation by Talin Barisani-Asenbauer of the Center for Pathophysiology, Infectiology & Immunology and the Laura Bassi Center at MedUni Vienna. The results of the VISUAL-I study have now been published in the leading journal New England Journal of Medicine.
  "We were able to prospectively demonstrate for the very first time that non-infectious uveitis can also be successfully treated with a cortisol-free medication. That will significantly improve the management of uveitis patients who have only partially responded to corticosteroids, need a corticosteroid sparing therapy or who are unsuitable for treatment with corticosteroids," explains Barisani-Asenbauer. The biologic medication adalimumab has long been used to treat rheumatic diseases and has to be injected subcutaneously every two weeks. For sufferers, steroid-free means there are fewer side-effects, so that it can be used over a longer period of time.
In Europe, up to 5/10,000 people (Source: www.orpha.net) suffer from some form of uveitis. Non-anterior, non-infectious uveitis, which was the subject of the recent study, affects around 40% of sufferers. Uveitis is the name used for inflammatory conditions of the inner eye, in particular the uvea, which consists of the iris and the ciliary body in the front section and the choroid in the back section.
Inflammation can also affect other parts of the eye, such as the retina and the vitreous body. 70 -- 90% of sufferers are aged between 20 and 60 and are in the middle of their working lives. The first symptoms are floaters in the visual field, blurred vision, visual disturbances and photosensitivity. Potential complications of uveitis are macular oedema (accumulation of fluid in the retina), glaucoma or cataracts, for example. Uveitis can even lead to loss of vision.
 

---

http://www.nejm.org/doi/10.1056/NEJMoa1509852